Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 4/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217445 | 0.79 | MAPT (0.51) | LMNASMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL7363823 | 0.78 | LMNA (0.60) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL15372902 | 0.77 | SLC1A3 (0.62) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL10825360 | 0.77 | SLC1A3 (0.62) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL18732911 | 0.76 | LMNA (0.65) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL10825548 | 0.76 | SLC1A3 (0.65) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL10825552 | 0.76 | SLC1A3 (0.65) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL1429727 | 0.74 | SLC1A3 (0.56) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL29401172 | 0.74 | SLC1A3 (0.78) | SLC1A3SLC1A1LMNASMN1; SMN2HTT | |
| SCHEMBL8390660 | 0.74 | SLC1A3 (0.78) | SLC1A3SLC1A1LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309207-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2016-04-12 | — | — | US | disclosed |
| US-9126955-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20140206760-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI (FR) | 2014-07-24 | — | — | US | disclosed |
| US-8722655-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINC1 | SLC1A3 4227/4885SLC1A1 4503/4885LMNA 1810/4885 |
| US-20140206760-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | SLC1A3 4221/4885SLC1A1 4506/4885LMNA 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.